Patient recruitment completed in Phase II stroke clinical trial
Pencoed, UK, 13 June 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with its stroke programme. The Company has completed patient recruitment in the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate in patients with motor disability as a result of ischaemic stroke.
CEO Presents at Cell & Gene Therapy Investor Day March 2016
BBC Breakfast interviews patient in ReNeuron’s Phase II stroke clinical trial
Pro-Active Investors : ReNeuron making good progress in clinical trials, says CFO
BBC News reports on patient treated in ReNeuron Phase II stroke clinical trial
A great-grandfather becomes one of the first in the UK to be treated for a stroke, using stem cells.
BBC News reports on patient treated in ReNeuron Phase II stroke clinical trial
A great-grandfather becomes one of the first in the UK to be treated for a stroke, using stem cells.
CEO presents at the 2015 Stem Cell meeting on the MESA
BBC Radio 5 Live Interview with Frank Marsh – 31st December 2013
Further data from first clinical trial of ReNeuron’s stem cell therapy for stroke to be presented at leading stroke conference
Guildford, UK, 7 May 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L) today provides a further update on the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients ahead of the commencement of a Phase II efficacy study for which patient enrolment has now opened.